Interference No. 103,675
In January 1992, the Compound Control Department received
Dr. Chen's request for testing and assigned the sample Bristol-Myers
Squibb number BMS-183583-01 (CX 59). The compound was determined to
exhibit tubulin polymerization and stabilization properties and in
vitro activity against certain cancer cells (CX 182, 183; CX 203). The
results were forwarded to Dr. Chen who forwarded them to Dr. Farina.
While this evidence may establish that a particular sample was tested
the evidence does not establish what was the identity of the sample
tested.
BMS-183821-01
According to Dr. Chen, he prepared a mixture of 2'-O-
benzloxycarbonyl-7-deoxy-8-desmethyl-7,8-cyclopropataxol and its ring
contracted analog as evidenced by the procedure set forth in his
laboratory notebook 32044 at page 011 in mid-December 1991 (CX 61).
According to Dr. Chen the procedures for preparing the protected
starting materials used to prepare the mixture of compounds in CX 61
are described in Dr. Chen's laboratory notebook number 32097 at pages
074 and 075 (CX 62 and CX 63, respectively). Dr. Chen subsequently
submitted a sample along with a sample submission form to the
Analytical Department and Ms. Huang performed the requested analysis
in early January 1992 (CX 65; CX 107). According to Chen et al., the
data collected by Ms. Huang was "re-plotted" in 1996 and the "re-
118
Page: Previous 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 Next
Last modified: November 3, 2007